Abstract: The present invention relates to a four-way conversion catalyst for the treatment of an exhaust gas stream of a gasoline engine, the catalyst comprising a porous wall-flow filter substrate comprising an inlet end, an outlet end, a substrate axial length extending between the inlet end and the outlet end, and a plurality of passages defined by porous internal walls of the porous wallflow filter substrate, wherein the plurality of passages comprise inlet passages having an open inlet end and a closed outlet end, and outlet passages having a closed inlet end and an open outlet end, wherein the interface between the passages and the porous internal walls is defined by the surface of the internal walls; wherein the porous internal walls comprise pores which comprise an oxidic component comprising a first refractory metal oxide, said first refractory metal oxide comprising aluminum, said oxidic component having a platinum group metal content in the range of from 0 to 0.

Abstract: Compound I of the formula and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

Abstract: Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

Abstract: A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.

Abstract: Compound I of the formula (formula) A pharmaceutically acceptable salt of Compound I. Pharmaceutical compositions containing at least Compound I and methods of treating cystic fibrosis comprising administering at least Compound I. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound I.

Abstract: A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.

Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Compound I of the formula (formula) A pharmaceutically acceptable salt of Compound I. Pharmaceutical compositions containing at least Compound I and methods of treating cystic fibrosis comprising administering at least Compound I. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound I.

Abstract: Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of Compound I.

Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Methods of treating cystic fibrosis comprising administering at least Compound (I) of the formula. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound (I).

Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

Abstract: A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.

Abstract: A machine learning system for ranking a collection of filtered propensity to failure metrics of like components within an electrical grid that includes a raw data assembly to provide raw data representative of the like components within the electrical grid; (b) a data processor, operatively coupled to the raw data assembly, to convert the raw data to more uniform data via one or more data processing techniques; (c) a database, operatively coupled to the data processor, to store the more uniform data; (d) a machine learning engine, operatively coupled to the database, to provide a collection of propensity to failure metrics for the like components; (e) an evaluation engine, operatively coupled to the machine learning engine, to detect and remove non-complying metrics from the collection of propensity to failure metrics and to provide the collection of filtered propensity to failure metrics; and (f) a decision support application, operatively coupled to the evaluation engine, configured to display a ranking of

Abstract: A machine learning system for ranking a collection of filtered propensity to failure metrics of like components within an electrical grid that includes a raw data assembly to provide raw data representative of the like components within the electrical grid; (b) a data processor, operatively coupled to the raw data assembly, to convert the raw data to more uniform data via one or more data processing techniques; (c) a database, operatively coupled to the data processor, to store the more uniform data; (d) a machine learning engine, operatively coupled to the database, to provide a collection of propensity to failure metrics for the like components; (e) an evaluation engine, operatively coupled to the machine learning engine, to detect and remove non-complying metrics from the collection of propensity to failure metrics and to provide the collection of filtered propensity to failure metrics; and (f) a decision support application, operatively coupled to the evaluation engine, configured to display a ranking of

Abstract: A one piece molded plastic foundation ventilator. The ventilator includes a one-piece continuous and structurally jointless plastic tubular member having a first through passageway, with the tubular member having a front and a rear, and with the through passageway of the ventilator including a portion between the front and the rear having a smaller cross-sectional dimension than the front, and having a smaller cross-sectional dimension than the rear. The front and rear of the ventilator includes outwardly directed flange portions. The ventilator may be supplemented by the addition of a screen and a hinged cover with securing latches.

Abstract: A ridge type roof vent. A roof vent is provided for use on a ridge of a roof. The vent has grillee portions flexibly located longitudinally along the lateral edges. The grille portions have at their distal end a set of flexible teeth adapted to fit on shingles and down between shingles in the gaps therebetween, so as to prevent passage between the grille and the shingle of any debris, insects, or vermin. The grille portions have void defining structures therein adapted to receive therethrough a nail guide and support, which guide is suitable for locating a nail to affix the vent to a roof. The vent is manufactured in a flat configuration, and thus it is capable of being easily packed and shipped. When folded at the hinged bends by the installer, the vent provides full venting capability while protecting against passage therethrough of unwanted debris, insects, or vermin.